78056-40-3

Usage

Core Structure

Piperazine

Attached Group

Trifluoromethylphenyl

Primary Use

Intermediate in the synthesis of pharmaceuticals and other organic compounds

Applications

a. Antimicrobial and antiviral agents
b. CNS-active drugs
c. Potential antidepressant and anxiolytic properties
d. Treatment of schizophrenia and Parkinson's disease

Industry

Pharmaceutical and medical industries

Versatility

Wide range of applications in the pharmaceutical and medical industries

Upstream product

• 109-70-6 1.3-chlorobromopropane 
• 15532-75-9 1-(3-Trifluoromethylphenyl)piperazine 
• 76835-14-8 1-[3-(trifluoromethyl)phenyl]piperazine hydrochloride 
• 5464-78-8 1-(2-methoxyphenyl)piperazine hydrochloride 

Downstream Products

• 134337-00-1 3-<3-<4-<3-(trifluoromethyl)phenyl>-1-piperazinyl>propyl>oxazolo<4,5-b>pyridin-2(3H)-one 
• 81514-01-4 <(m-trifluoromethyl phenyl-4 piperazinyl-1)-3 propyl-1>-3 benzoxazolinone 
• 81514-08-1 6-Ethyl-3-{3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-propyl}-3H-benzooxazol-2-one 
• 81514-06-9 6-Acetyl-3-{3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-propyl}-3H-benzooxazol-2-one 
• 81514-07-0 6-Propionyl-3-{3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-propyl}-3H-benzooxazol-2-one 
• 81514-04-7 6-Benzoyl-3-{3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-propyl}-3H-benzooxazol-2-one 
• 81514-05-8 6-(2-Chloro-benzoyl)-3-{3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-propyl}-3H-benzooxazol-2-one 
• 115762-30-6 1-[3-(4-(3-Trifluoromethylphenyl)piperazin1-yl)propylmercapto]-s-triazolo(4,3-a)quinoline 
• 115762-32-8 1-[3-(4-(3-trifluoromethylphenyl)piperazin-1-yl)propylmercapto]-4-methyl-s-triazolo(4,3-a)quinoline 
• 1034266-26-6 C₂₄H₂₆F₃N₃O₂S 
• 1149351-83-6 2,3,4,5-tetrahydro-N-[3-(4-(3-trifluoromethylphenyl)piperazin-1-yl)propyl]benzo[c]azepin-1-one 

Relevant academic research and scientific papers

Benzo-aza-alkyl aryl piperazine derivative and applications in preparation of drugs

The invention discloses a benzo-aza-alkyl aryl piperazine derivative and applications in preparation of drugs. The derivative shows the effect on central nervous systems, especially on the double highaffinity activity of a 5-HT acceptor and a Sigma-1 acceptor. Various physiological and pharmacological effects are brought into play in the body; and the compound can be used as a pharmaceuticalactive substance, especially used for anti-depression, anti-anxiety, anti-bipolar affective disorder and anti-neuropathic pain, and can also be used as an intermediate to prepare other pharmaceuticalactive compounds. The compound is fast in effect and small in toxic and side effect, and can meet demands of clinical applications; and the compound is a compound or a free base or salt thereof havingthe following structural formula (IV). The structure of the compound or the free base or salt thereof is shown as the structural formula (IV).

Synthesis, 3D-QSAR, and structural modeling of benzolactam derivatives with binding affinity for the D2and D3 receptors

A series of 37 benzolactam derivatives were synthesized, and their respective affinities for the dopamine D2 and D3 receptors evaluated. The relationships between structures and binding affinities were investigated using both ligand-based (3D-QSAR) and receptor-based methods. The results revealed the importance of diverse structural features in explaining the differences in the observed affinities, such as the location of the benzolactam carbonyl oxygen, or the overall length of the compounds. The optimal values for such ligand properties are slightly different for the D2 and D 3 receptors, even though the binding sites present a very high degree of homology. We explain these differences by the presence of a hydrogen bond network in the D2 receptor which is absent in the D3 receptor and limits the dimensions of the binding pocket, causing residues in helix 7 to become less accessible. The implications of these results for the design of more potent and selective benzolactam derivatives are presented and discussed.

TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS

A method of treating exposure to organophosphate agents through the use of compounds comprising tetrahydroindolone and arylpiperazine moieties.

Synthesis, binding affinity and SAR of new benzolactam derivatives as dopamine D3 receptor ligands

A series of new benzolactam derivatives was synthesized and the derivatives were evaluated for their affinities at the dopamine D1, D2, and D3 receptors. Some of these compounds showed high D2 and/or D3/su

Preparation of piperazine derivatives as 5-HT7 receptor antagonists

Twenty-four compounds of 4-methoxy-N-[3-(4-substituted phenyl-piperazine-1-yl)propyl] benzene sulfonamides and N-[3-(4-substituted phenyl-piperazine-1-yl)propyl] naphthyl sulfonamides were prepared and evaluated as 5-HT7 receptor antagonists. Most of the compounds showed the IC50 values of 12-580 nM. Four methyl branched analogues were also obtained, but the activity for methyl branched analogues was almost same as its straight chain congeners. Among the synthesized compounds, 3c showed a good activity on 5-HT7 receptors and a good selectivity on 5-HT1a, 5-HT2a, 5-HT2c, and 5-HT6 receptors.

Synthesis of new piperazine-pyridazinone derivatives and their binding affinity toward α1-, α2-adrenergic and 5-HT1A serotoninergic receptors

We report the design and synthesis of a new class of piperazine- pyridazinone analogues. The arylpiperazine moiety, the length of the spacer, and the terminal molecular fragment were varied to evaluate their influence in determining the affinity of the new compounds toward the α1- adrenergic receptor (α1-AR), α2-adrenergic receptor (α2-AR), and the 5-HT1A serotoninergic receptor (5-HT1AR). Biological data showed that most of the compounds have an α1-AR affinity in the nanomolar or subnanomolar range, while affinity toward the other two receptors was lower in most cases. However, several of the tested compounds also showed very good (in the nanomolar range) or moderate affinity toward the 5-HT1AR subtype.

Composition and method for treating emesis

Methods for treating emesis using compositions comprising a bicyclic ring moiety covalently linked to a substituted arylpiperazine moiety are disclosed.

Microwave-assisted solvent-free synthesis of 3-[(4-substituted piperazin-1-yl)alkyl] imidazo[2,1-b][1,3]benzothiazol-2(3H)-ones as serotonin3 (5-HT3) receptor antagonists

A series of novel 3-[(4-substituted piperazin-1-yl)alkyl]imidazo[2,1-b][1, 3]benzothiazol-2(3H)-ones were prepared by microwave irradiation using alumina as solid support and also by a conventional method. The compounds were characterized by spectral data and the purity was ascertained by microanalysis. The synthesized compounds were evaluated for 5-hydroxytryptamine3 antagonisms in a longitudinal muscle-myenteric plexus preparation from guinea pig ileum against the 5-hydroxytryptamine3 agonist, 2-methyl-5-hydroxytryptamine. Among the test compounds, 3-[2-(4-methylpiperazin- 1-yl)ethyl]imidazo[2,1-6][1,3]benzothiazol-2(3H)-one (3b) showed most favorable 5-hydroxytryptamine3 antagonism (pA2 6.7) in the isolated guinea pig ileum.

Tetrahydroindolone and purine derivatives linked to arylpiperazines

Pharmaceutical composite compositions comprising tetrahydroindolones linked to arylpiperazines and derivatives thereof are disclosed. Specifically, composite compositions useful in treating anti-psychotic disorders are disclosed. The composite compositions disclosed herein can effectively ameliorate symptoms and treat psychotic disorders without causing a decrease in cognitive function. Generally, the composite compounds consist of two moieties, moiety A and B in which a tetrahydroindolone comprises a moiety A linked through a linker L to a moiety B, where B is an arylpiperazinyl moiety. The composite compound provides anti-psychotic actively by interaction with GABA, seratoninne and dopamine receptors. The composite molecules with the combined activities will provide treat psychiatric and neurological diseases without cognitive impairment.

TETRAHYDROINDOLONE AND PURINE DERIVATIVES LINKED TO ARYLPIPERAZINES

Pharmaceutical composite compositions comprising tetrahydroindolones linked to arylpiperazines and derivatives thereof are disclosed. Specifically, composite compositions useful in treating anti-psychotic disorders are disclosed. The composite compositions disclosed herein can effectively ameliorate symptoms and treat psychotic disorders without causing a decrease in cognitive function. Generally, the composite compounds consist of two moieties, moiety A and B in which a tetrahydroindolone comprises a moiety A linked through a linker L to a moiety B, where B is an arylpiperazinyl moiety. The composite compound provides anti-psychotic actively by interaction with GABA, seratoninne and dopamine receptors. The composite molecules with the combined activities will provide treat psychiatric and neurological diseases without cognitive impairment.